Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Carboplatin + PF-08046876 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| PF-08046876 | PF 08046876|PF08046876 | PF-08046876 is an antibody-drug conjugate (ADC) comprising an antibody targeting integrin beta-6 (IB6) linked to a camptothecin-class topoisomerase I inhibitor, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1577). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07090499 | Phase I | Carboplatin + Pembrolizumab + PF-08046876 Pembrolizumab + PF-08046876 Carboplatin + PF-08046876 Cisplatin + PF-08046876 PF-08046876 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | CAN | 2 |